title: ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.
abstract: ErbB receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ErbB inhibitors are now used in the clinical setting. A large number of studies have been conducted to examine the expression of ErbB family members in bone and soft tissue sarcomas, including osteosarcomas, synovial sarcomas, Ewing sarcomas, rhabdomyosarcomas, and so on. Nevertheless, the clinical implications of ErbB receptors remain elusive. To illustrate the potential of ErbB family members as prognostic and therapeutic drug targets in bone and soft tissue sarcomas, we summarized the molecular evidence and observations from clinical and basic trials.
authors.affiliation: 1Department of Orthopedics, Shanghai 1st People's Hospital, Shanghai Jiaotong University, Shanghai, China.
authors.forename: Hongsheng
authors.initials: H
authors.lastname: Wang
authors.forename: Qingbo
authors.initials: Q
authors.lastname: Yang
authors.forename: Zeze
authors.initials: Z
authors.lastname: Fu
authors.forename: Dongqing
authors.initials: D
authors.lastname: Zuo
authors.forename: Yingqi
authors.initials: Y
authors.lastname: Hua
authors.forename: Zhengdong
authors.initials: Z
authors.lastname: Cai
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy; D012509:Sarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D066246:ErbB Receptors
keywords: Bone and soft tissue sarcomas; ErbB receptors; Prognostic relevance; Targeted therapy